Response criteria and MRD

Hepatic response criteria in light chain amyloidosis: a multicenter validation study

Muchtar E, Palladini G, Schonland S, …, Szalat R, …, Gertz MA

HaematologicaDOI: Hepatic response criteria in light chain amyloidosis: a multicenter validation studyPubMed: Hepatic response criteria in light chain amyloidosis: a multicenter validation study

Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

Muchtar E, Wisniowski B, Geyer S, …, Szalat R, …, Gertz MA

JAMA Oncology10(10):1362DOI: Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisPubMed: Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

Role of minimal residual disease assessment in multiple myeloma

Szalat R, Anderson K, Munshi N

Haematologica109(7):2049-2059DOI: Role of minimal residual disease assessment in multiple myelomaPubMed: Role of minimal residual disease assessment in multiple myeloma

Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

Muchtar E, Dispenzieri A, Wisniowski B, …, Szalat R, …, Gertz MA

Journal of Clinical Oncology41(7):1393-1403DOI: Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisPubMed: Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

Gustine JN, Staron A, Szalat RE, …, Sanchorawala V

American Journal of Hematology97(9):1189-1199DOI: Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal studyPubMed: Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V

Leukemia35(3):916-919DOI: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosisPubMed: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Cohen C, Royer B, Javaugue V, Szalat R, …, Bridoux F

Kidney International88(5):1135-1143DOI: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition diseasePubMed: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

Fouquet G, Hebraud B, Garciaz S, …, Szalat R, …, Leleu X

Journal of Cancer5(3):248-252DOI: Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in ConsolidationPubMed: Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, (IFM) OBOIFDM

Leukemia27(11):2242-2244DOI: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaPubMed: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

Staron A, Burks EJ, Szalat RE, Sanchorawala V

Blood142(Supplement 1):3405-3405DOI: Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Muchtar E, Dispenzieri A, Wisniowski B, …, Szalat R, …, Gertz MA

Blood138(Supplement 1):2720-2720DOI: Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Muchtar E, Wisniowski B, Palladini G, …, Szalat R, …, Gertz MA

Blood138(Supplement 1):2721-2721DOI: Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis

Muchtar E, Wisniowski B, Palladini G, …, Szalat R, …, Gertz M

Clinical Lymphoma Myeloma and Leukemia21:S23-S24DOI: OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis

CONSOLIDATION WITH VTD SIGNIFICANTLY IMPROVES THE COMPLETE REMISSION RATE IN MULTIPLE MYELOMA

Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML, et al.

HAEMATOLOGICA98:100-100

Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd

Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, Moreau P

Blood122(21):3221-3221DOI: Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd

Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).

Leleu X, Hebraud B, Fouquet G, …, Szalat R, …, Moreau P

Blood120(21):3096-3096DOI: Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).